Bioniz Therapeutics Appoints Fredrik Wiklund as Chief Operating Officer
Irvine, CA, May 3rd, 2016 — Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively inhibit multiple cytokines to address immuno-inflammatory diseases and cancer, announced today that it has appointed Fredrik Wiklund as its Chief Operating Officer. Over the last twenty years, Mr. Wiklund has amassed a wealth of operational and executive experience in the biotechnology industry with a proven track record in executing private and public financings, high-value partnering transactions, building commercial expertise in innovation-based companies and driving strategic growth.
As a key member of the executive leadership team, Mr. Wiklund will be responsible for leading the company’s business, operations, strategy, corporate development, finance, commercial planning, investor relations and corporate communications.
“Bioniz is excited to welcome Fred who brings to our team broad experience in operations, strategy and execution in emerging biopharmaceutical companies,” said Nazli Azimi, Ph.D., Founder, President and Chief Executive Officer. “Fred’s business acumen and proven leadership will strengthen our ability to enhance our platform to generate novel peptide therapeutic candidates that selectively inhibit multiple cytokines into product opportunities in areas of high unmet medical need.”
Mr. Wiklund commented, “I am thrilled to be joining Bioniz, an exciting, emerging company with a truly novel approach to addressing autoimmune diseases and cancer. Bioniz’s solution to solving cytokine redundancy by developing peptide therapeutics that can selectively target only those cytokines that exhibit overlapping functions offers a unique opportunity to bring a new class of potentially disruptive therapies to patients. I look forward to helping Bioniz realize its vision to create the next generation of immune therapies.”
Mr. Wiklund joins Bioniz from Celladon Corporation where he served as Vice President, Corporate Development and Investor Relations. He also served as President and Chief Executive Officer as the company merged with Eiger Biopharmaceuticals. During his time at Celladon, Fred led the company through multiple financings including its Initial Public Offering (IPO) and the subsequent merger. Prior to Celladon, Fred served as Head of Corporate Development and Investor Relations at Tercica, Inc. During his 5 years at Tercica, Fred assisted in the company’s IPO and also executed strategic transactions exceeding $800M, including the company’s sale to the Ipsen Group in 2008. Previously, Fred was an investment banker with Lehman Brothers where he assisted pharmaceutical and emerging biotechnology companies complete capital-raising and strategic transactions. Fred also has over 7 years of commercial experience, primarily with Gilead Sciences where he participated in the company’s first product launch in 1996.
Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases that have an immune component. Bioniz leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to develop a novel approach to selectively inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor. Bioniz’ innovative platform has resulted in multiple peer-reviewed publications in notable scientific journals. For more information, please visit www.bioniz.com.